Abstract
Pneumococcal disease remains a significant cause of morbidity and mortality in adults, particularly those over 65. This paper synthesizes the clinical guidelines established by the Respiratory Diseases Group (GRESP) for the Portuguese adult population. It outlines a sequential vaccination strategy using the 13-valent conjugate vaccine (VPC13) and the 23-valent polysaccharide vaccine (VPP23) to optimize immune memory and serotype coverage.
Introduction
Streptococcus pneumoniae is responsible for a wide spectrum of diseases, ranging from non-invasive conditions like sinusitis to life-threatening invasive pneumococcal disease (IPD) such as meningitis and sepsis. In Portugal, Community-Acquired Pneumonia (CAP) represents a substantial healthcare burden, accounting for approximately 4% of adult hospitalizations. The risk is significantly elevated in the elderly, with those aged 65 and older experiencing hospitalization rates nearly four times higher than the general adult population. To address this, GRESP provides actionable vaccination algorithms based on national and international standards.
Methods and Vaccination Strategy
The GRESP recommendations are based on a synthesis of Portuguese national health norms (DGS Norm 011/2015) and international guidelines. The cornerstone of the recommended approach is the sequential administration of two distinct vaccine types:
- VPC13 (Conjugate Vaccine): This vaccine induces a T-cell dependent immune response, which is essential for developing long-term immune memory and improving mucosal immunity.
- VPP23 (Polysaccharide Vaccine): This vaccine provides broader protection against 23 different serotypes but does not induce long-term immune memory.
The "prime-boost" strategy involves administering VPC13 first to prime the immune system, followed by VPP23 to expand the breadth of protection. The standard interval between these doses is 6 to 12 months, though it may be reduced to a minimum of 8 weeks for high-risk individuals.
Key Recommendations and Risk Stratification
GRESP categorizes patients to determine the appropriate vaccination schedule and state funding eligibility:
- Immunocompetent Adults (≥ 65 years): Vaccination is recommended for all individuals in this age group, regardless of risk factors, to counteract immunosenescence.
- High-Risk Groups: This includes both immunocompetent individuals with chronic conditions (e.g., heart or lung disease, diabetes) and immunocompromised patients (e.g., HIV, asplenia).
- Correction of Prior Vaccination: For adults previously vaccinated with VPP23 alone, a "catch-up" logic ensures they receive the VPC13 dose to benefit from conjugate-induced immune memory.
Results and Epidemiological Context
Epidemiological data underscores the necessity of these guidelines. In Portugal, CAP hospitalizations average 3.61 per 1,000 inhabitants, but this figure rises sharply to 13.4 per 1,000 for those aged 65 and older. The sequential strategy aims to mitigate this burden by combining the robust biological response of VPC13 with the extensive serotype coverage of VPP23.
Discussion and Conclusion
The primary insight of the GRESP guidelines is the critical importance of vaccine sequencing. Administering VPP23 before VPC13 can lead to "immune blunting" (immune interference), reducing the effectiveness of subsequent doses. By standardizing these intervals and expanding recommendations to all adults over 65, GRESP aims to simplify clinical decision-making and improve vaccination uptake. While challenges such as serotype replacement and implementation barriers remain, these structured algorithms provide a clear roadmap for healthcare providers to reduce the impact of pneumococcal disease in Portugal.
Summary updated